Serveur d'exploration MERS

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Atheroprotective vaccination with MHC-II-restricted ApoB peptides induces peritoneal IL-10-producing CD4 T cells.

Identifieur interne : 000E15 ( PubMed/Corpus ); précédent : 000E14; suivant : 000E16

Atheroprotective vaccination with MHC-II-restricted ApoB peptides induces peritoneal IL-10-producing CD4 T cells.

Auteurs : Takayuki Kimura ; Kevin Tse ; Sara Mcardle ; Teresa Gerhardt ; Jacqueline Miller ; Zbigniew Mikulski ; John Sidney ; Alessandro Sette ; Dennis Wolf ; Klaus Ley

Source :

RBID : pubmed:28087520

English descriptors

Abstract

Although immunization with major histocompatibility complex (MHC) class II-restricted apolipoprotein B (ApoB) peptides has been shown to be atheroprotective, the mechanism is unclear. Here, we investigated CD4+ T cell populations in immunized atherosclerotic mice. Peptides (16-mers) from mouse ApoB, the core protein of low-density lipoprotein (LDL), were screened for binding to I-Ab by computer prediction and confirmed by radiolabeled peptide competition. Three new peptides, P101 (FGKQGFFPDSVNKALY, 5.5 nM IC50), P102 (TLYALSHAVNSYFDVD, 6.8 nM), and P103 (LYYKEDKTSLSASAAS, 95 nM), were tested in an atherosclerosis model (Apoe-/- mice on Western diet). Immunization with each of the three peptides (1 time in complete Freund's adjuvant subcuntaneously and 4 time in incomplete Freund's adjuvant intraperitoneally) but not with adjuvant alone showed significantly reduced atherosclerotic plaques in the aortic root by serial sections and in the whole aorta by en face staining. There were no differences in body weight, LDL cholesterol, or triglycerides. Peritoneal leukocytes from ApoB peptide-immunized mice, but not control mice, secreted significant amounts of IL-10 (150 pg/ml). Flow cytometry showed that peptide immunization induced IL-10 in 10% of peritoneal CD4+ T cells, some of which also expressed chemokine (C-C motif) receptor 5 (CCR5). Vaccination with ApoB peptides expanded peritoneal FoxP3+ regulatory CD4+ T cells and more than tripled the number of CCR5+FoxP3+ cells. Similar trends were also seen in the draining mediastinal lymph nodes but not in the nondraining inguinal lymph nodes. We conclude that vaccination with MHC class II-restricted autologous ApoB peptides induces regulatory T cells (Tregs) and IL-10, suggesting a plausible mechanism for atheroprotection.NEW & NOTEWORTHY Vaccination against apolipoprotein B (ApoB), the protein of LDL, attracts attention as a novel approach to prevent atherosclerosis. We discovered major histocompatibility complex class II-restricted ApoB peptides, which reduce atherosclerosis and induce IL-10-producing CD4+ T cells and chemokine (C-C motif) receptor 5 expression on regulatory T cells, suggesting that immunization with ApoB peptides inhibits atherosclerosis by inducing anti-inflammatory cytokines.

DOI: 10.1152/ajpheart.00798.2016
PubMed: 28087520

Links to Exploration step

pubmed:28087520

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Atheroprotective vaccination with MHC-II-restricted ApoB peptides induces peritoneal IL-10-producing CD4 T cells.</title>
<author>
<name sortKey="Kimura, Takayuki" sort="Kimura, Takayuki" uniqKey="Kimura T" first="Takayuki" last="Kimura">Takayuki Kimura</name>
<affiliation>
<nlm:affiliation>Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California; and.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Tse, Kevin" sort="Tse, Kevin" uniqKey="Tse K" first="Kevin" last="Tse">Kevin Tse</name>
<affiliation>
<nlm:affiliation>Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California; and.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Mcardle, Sara" sort="Mcardle, Sara" uniqKey="Mcardle S" first="Sara" last="Mcardle">Sara Mcardle</name>
<affiliation>
<nlm:affiliation>Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California; and.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Gerhardt, Teresa" sort="Gerhardt, Teresa" uniqKey="Gerhardt T" first="Teresa" last="Gerhardt">Teresa Gerhardt</name>
<affiliation>
<nlm:affiliation>Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California; and.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Miller, Jacqueline" sort="Miller, Jacqueline" uniqKey="Miller J" first="Jacqueline" last="Miller">Jacqueline Miller</name>
<affiliation>
<nlm:affiliation>Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California; and.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Mikulski, Zbigniew" sort="Mikulski, Zbigniew" uniqKey="Mikulski Z" first="Zbigniew" last="Mikulski">Zbigniew Mikulski</name>
<affiliation>
<nlm:affiliation>Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California; and.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Sidney, John" sort="Sidney, John" uniqKey="Sidney J" first="John" last="Sidney">John Sidney</name>
<affiliation>
<nlm:affiliation>Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Sette, Alessandro" sort="Sette, Alessandro" uniqKey="Sette A" first="Alessandro" last="Sette">Alessandro Sette</name>
<affiliation>
<nlm:affiliation>Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Wolf, Dennis" sort="Wolf, Dennis" uniqKey="Wolf D" first="Dennis" last="Wolf">Dennis Wolf</name>
<affiliation>
<nlm:affiliation>Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California; and.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Ley, Klaus" sort="Ley, Klaus" uniqKey="Ley K" first="Klaus" last="Ley">Klaus Ley</name>
<affiliation>
<nlm:affiliation>Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California; and klaus@lji.org.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:28087520</idno>
<idno type="pmid">28087520</idno>
<idno type="doi">10.1152/ajpheart.00798.2016</idno>
<idno type="wicri:Area/PubMed/Corpus">000E15</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000E15</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Atheroprotective vaccination with MHC-II-restricted ApoB peptides induces peritoneal IL-10-producing CD4 T cells.</title>
<author>
<name sortKey="Kimura, Takayuki" sort="Kimura, Takayuki" uniqKey="Kimura T" first="Takayuki" last="Kimura">Takayuki Kimura</name>
<affiliation>
<nlm:affiliation>Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California; and.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Tse, Kevin" sort="Tse, Kevin" uniqKey="Tse K" first="Kevin" last="Tse">Kevin Tse</name>
<affiliation>
<nlm:affiliation>Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California; and.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Mcardle, Sara" sort="Mcardle, Sara" uniqKey="Mcardle S" first="Sara" last="Mcardle">Sara Mcardle</name>
<affiliation>
<nlm:affiliation>Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California; and.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Gerhardt, Teresa" sort="Gerhardt, Teresa" uniqKey="Gerhardt T" first="Teresa" last="Gerhardt">Teresa Gerhardt</name>
<affiliation>
<nlm:affiliation>Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California; and.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Miller, Jacqueline" sort="Miller, Jacqueline" uniqKey="Miller J" first="Jacqueline" last="Miller">Jacqueline Miller</name>
<affiliation>
<nlm:affiliation>Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California; and.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Mikulski, Zbigniew" sort="Mikulski, Zbigniew" uniqKey="Mikulski Z" first="Zbigniew" last="Mikulski">Zbigniew Mikulski</name>
<affiliation>
<nlm:affiliation>Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California; and.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Sidney, John" sort="Sidney, John" uniqKey="Sidney J" first="John" last="Sidney">John Sidney</name>
<affiliation>
<nlm:affiliation>Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Sette, Alessandro" sort="Sette, Alessandro" uniqKey="Sette A" first="Alessandro" last="Sette">Alessandro Sette</name>
<affiliation>
<nlm:affiliation>Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Wolf, Dennis" sort="Wolf, Dennis" uniqKey="Wolf D" first="Dennis" last="Wolf">Dennis Wolf</name>
<affiliation>
<nlm:affiliation>Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California; and.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Ley, Klaus" sort="Ley, Klaus" uniqKey="Ley K" first="Klaus" last="Ley">Klaus Ley</name>
<affiliation>
<nlm:affiliation>Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California; and klaus@lji.org.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series>
<title level="j">American journal of physiology. Heart and circulatory physiology</title>
<idno type="eISSN">1522-1539</idno>
<imprint>
<date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Amino Acid Sequence</term>
<term>Animals</term>
<term>Apolipoproteins B (immunology)</term>
<term>Apolipoproteins E (genetics)</term>
<term>Apolipoproteins E (immunology)</term>
<term>Atherosclerosis (immunology)</term>
<term>Atherosclerosis (pathology)</term>
<term>Atherosclerosis (prevention & control)</term>
<term>CD4-Positive T-Lymphocytes (immunology)</term>
<term>CD4-Positive T-Lymphocytes (metabolism)</term>
<term>Female</term>
<term>Forkhead Transcription Factors (metabolism)</term>
<term>Genes, MHC Class II (immunology)</term>
<term>Immunoglobulin G (immunology)</term>
<term>Interleukin-10 (biosynthesis)</term>
<term>Lipoproteins, LDL (immunology)</term>
<term>Lymph Nodes (cytology)</term>
<term>Lymph Nodes (immunology)</term>
<term>Mice</term>
<term>Mice, Inbred C57BL</term>
<term>Mice, Knockout</term>
<term>Peptides (immunology)</term>
<term>Vaccination</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en">
<term>Interleukin-10</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en">
<term>Apolipoproteins E</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en">
<term>Apolipoproteins B</term>
<term>Apolipoproteins E</term>
<term>Immunoglobulin G</term>
<term>Lipoproteins, LDL</term>
<term>Peptides</term>
</keywords>
<keywords scheme="MESH" qualifier="cytology" xml:lang="en">
<term>Lymph Nodes</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en">
<term>Atherosclerosis</term>
<term>CD4-Positive T-Lymphocytes</term>
<term>Genes, MHC Class II</term>
<term>Lymph Nodes</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>CD4-Positive T-Lymphocytes</term>
<term>Forkhead Transcription Factors</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en">
<term>Atherosclerosis</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en">
<term>Atherosclerosis</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Amino Acid Sequence</term>
<term>Animals</term>
<term>Female</term>
<term>Mice</term>
<term>Mice, Inbred C57BL</term>
<term>Mice, Knockout</term>
<term>Vaccination</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Although immunization with major histocompatibility complex (MHC) class II-restricted apolipoprotein B (ApoB) peptides has been shown to be atheroprotective, the mechanism is unclear. Here, we investigated CD4
<sup>+</sup>
T cell populations in immunized atherosclerotic mice. Peptides (16-mers) from mouse ApoB, the core protein of low-density lipoprotein (LDL), were screened for binding to I-A
<sup>b</sup>
by computer prediction and confirmed by radiolabeled peptide competition. Three new peptides, P101 (FGKQGFFPDSVNKALY, 5.5 nM IC
<sub>50</sub>
), P102 (TLYALSHAVNSYFDVD, 6.8 nM), and P103 (LYYKEDKTSLSASAAS, 95 nM), were tested in an atherosclerosis model (
<i>Apoe
<sup>-/-</sup>
</i>
mice on Western diet). Immunization with each of the three peptides (1 time in complete Freund's adjuvant subcuntaneously and 4 time in incomplete Freund's adjuvant intraperitoneally) but not with adjuvant alone showed significantly reduced atherosclerotic plaques in the aortic root by serial sections and in the whole aorta by en face staining. There were no differences in body weight, LDL cholesterol, or triglycerides. Peritoneal leukocytes from ApoB peptide-immunized mice, but not control mice, secreted significant amounts of IL-10 (150 pg/ml). Flow cytometry showed that peptide immunization induced IL-10 in 10% of peritoneal CD4
<sup>+</sup>
T cells, some of which also expressed chemokine (C-C motif) receptor 5 (CCR5). Vaccination with ApoB peptides expanded peritoneal FoxP3
<sup>+</sup>
regulatory CD4
<sup>+</sup>
T cells and more than tripled the number of CCR5
<sup>+</sup>
FoxP3
<sup>+</sup>
cells. Similar trends were also seen in the draining mediastinal lymph nodes but not in the nondraining inguinal lymph nodes. We conclude that vaccination with MHC class II-restricted autologous ApoB peptides induces regulatory T cells (Tregs) and IL-10, suggesting a plausible mechanism for atheroprotection.
<b>NEW & NOTEWORTHY</b>
Vaccination against apolipoprotein B (ApoB), the protein of LDL, attracts attention as a novel approach to prevent atherosclerosis. We discovered major histocompatibility complex class II-restricted ApoB peptides, which reduce atherosclerosis and induce IL-10-producing CD4
<sup>+</sup>
T cells and chemokine (C-C motif) receptor 5 expression on regulatory T cells, suggesting that immunization with ApoB peptides inhibits atherosclerosis by inducing anti-inflammatory cytokines.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">28087520</PMID>
<DateCompleted>
<Year>2017</Year>
<Month>07</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2020</Year>
<Month>01</Month>
<Day>16</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1522-1539</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>312</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2017</Year>
<Month>Apr</Month>
<Day>01</Day>
</PubDate>
</JournalIssue>
<Title>American journal of physiology. Heart and circulatory physiology</Title>
<ISOAbbreviation>Am. J. Physiol. Heart Circ. Physiol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Atheroprotective vaccination with MHC-II-restricted ApoB peptides induces peritoneal IL-10-producing CD4 T cells.</ArticleTitle>
<Pagination>
<MedlinePgn>H781-H790</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1152/ajpheart.00798.2016</ELocationID>
<Abstract>
<AbstractText>Although immunization with major histocompatibility complex (MHC) class II-restricted apolipoprotein B (ApoB) peptides has been shown to be atheroprotective, the mechanism is unclear. Here, we investigated CD4
<sup>+</sup>
T cell populations in immunized atherosclerotic mice. Peptides (16-mers) from mouse ApoB, the core protein of low-density lipoprotein (LDL), were screened for binding to I-A
<sup>b</sup>
by computer prediction and confirmed by radiolabeled peptide competition. Three new peptides, P101 (FGKQGFFPDSVNKALY, 5.5 nM IC
<sub>50</sub>
), P102 (TLYALSHAVNSYFDVD, 6.8 nM), and P103 (LYYKEDKTSLSASAAS, 95 nM), were tested in an atherosclerosis model (
<i>Apoe
<sup>-/-</sup>
</i>
mice on Western diet). Immunization with each of the three peptides (1 time in complete Freund's adjuvant subcuntaneously and 4 time in incomplete Freund's adjuvant intraperitoneally) but not with adjuvant alone showed significantly reduced atherosclerotic plaques in the aortic root by serial sections and in the whole aorta by en face staining. There were no differences in body weight, LDL cholesterol, or triglycerides. Peritoneal leukocytes from ApoB peptide-immunized mice, but not control mice, secreted significant amounts of IL-10 (150 pg/ml). Flow cytometry showed that peptide immunization induced IL-10 in 10% of peritoneal CD4
<sup>+</sup>
T cells, some of which also expressed chemokine (C-C motif) receptor 5 (CCR5). Vaccination with ApoB peptides expanded peritoneal FoxP3
<sup>+</sup>
regulatory CD4
<sup>+</sup>
T cells and more than tripled the number of CCR5
<sup>+</sup>
FoxP3
<sup>+</sup>
cells. Similar trends were also seen in the draining mediastinal lymph nodes but not in the nondraining inguinal lymph nodes. We conclude that vaccination with MHC class II-restricted autologous ApoB peptides induces regulatory T cells (Tregs) and IL-10, suggesting a plausible mechanism for atheroprotection.
<b>NEW & NOTEWORTHY</b>
Vaccination against apolipoprotein B (ApoB), the protein of LDL, attracts attention as a novel approach to prevent atherosclerosis. We discovered major histocompatibility complex class II-restricted ApoB peptides, which reduce atherosclerosis and induce IL-10-producing CD4
<sup>+</sup>
T cells and chemokine (C-C motif) receptor 5 expression on regulatory T cells, suggesting that immunization with ApoB peptides inhibits atherosclerosis by inducing anti-inflammatory cytokines.</AbstractText>
<CopyrightInformation>Copyright © 2017 the American Physiological Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kimura</LastName>
<ForeName>Takayuki</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tse</LastName>
<ForeName>Kevin</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>McArdle</LastName>
<ForeName>Sara</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gerhardt</LastName>
<ForeName>Teresa</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Miller</LastName>
<ForeName>Jacqueline</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mikulski</LastName>
<ForeName>Zbigniew</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sidney</LastName>
<ForeName>John</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sette</LastName>
<ForeName>Alessandro</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wolf</LastName>
<ForeName>Dennis</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ley</LastName>
<ForeName>Klaus</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California; and klaus@lji.org.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P01 HL136275</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 HL121697</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2017</Year>
<Month>01</Month>
<Day>13</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am J Physiol Heart Circ Physiol</MedlineTA>
<NlmUniqueID>100901228</NlmUniqueID>
<ISSNLinking>0363-6135</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C415826">Apob protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001055">Apolipoproteins B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051858">Forkhead Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C498833">Foxp3 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C556062">IL10 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008077">Lipoproteins, LDL</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010455">Peptides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>130068-27-8</RegistryNumber>
<NameOfSubstance UI="D016753">Interleukin-10</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D001055" MajorTopicYN="N">Apolipoproteins B</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D050197" MajorTopicYN="N">Atherosclerosis</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D051858" MajorTopicYN="N">Forkhead Transcription Factors</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005802" MajorTopicYN="N">Genes, MHC Class II</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016753" MajorTopicYN="N">Interleukin-10</DescriptorName>
<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008077" MajorTopicYN="N">Lipoproteins, LDL</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008198" MajorTopicYN="N">Lymph Nodes</DescriptorName>
<QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014611" MajorTopicYN="Y">Vaccination</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">CCR5</Keyword>
<Keyword MajorTopicYN="N">FoxP3</Keyword>
<Keyword MajorTopicYN="N">IL-10</Keyword>
<Keyword MajorTopicYN="N">MHC class II</Keyword>
<Keyword MajorTopicYN="N">apolipoprotein B-100</Keyword>
<Keyword MajorTopicYN="N">atherosclerosis</Keyword>
<Keyword MajorTopicYN="N">immunization</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2016</Year>
<Month>12</Month>
<Day>05</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised">
<Year>2017</Year>
<Month>01</Month>
<Day>09</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2017</Year>
<Month>01</Month>
<Day>09</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2017</Year>
<Month>1</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2017</Year>
<Month>7</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2017</Year>
<Month>1</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">28087520</ArticleId>
<ArticleId IdType="pii">ajpheart.00798.2016</ArticleId>
<ArticleId IdType="doi">10.1152/ajpheart.00798.2016</ArticleId>
<ArticleId IdType="pmc">PMC5407161</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>J Exp Med. 2011 Jun 6;208(6):1279-89</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21606508</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Pathol. 2010 May;176(5):2177-87</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20382703</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Circ Res. 2016 May 13;118(10 ):1540-52</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">27021296</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Am Coll Cardiol. 2007 Aug 7;50(6):540-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17678738</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Invest. 2004 Aug;114(3):427-37</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15286809</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Autoimmunity. 2015 May;48(3):152-60</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25683179</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Curr Protoc Immunol. 2013 Feb;Chapter 18:Unit 18.3.</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23392640</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Circulation. 2003 Sep 9;108(10):1232-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12912803</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell. 1993 Oct 22;75(2):263-74</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8402911</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Circ Res. 2002 May 31;90(10):1064-71</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12039795</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Arterioscler Thromb Vasc Biol. 1998 Dec;18(12):1972-82</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9848892</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Front Immunol. 2013 Dec 27;4:493</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24416033</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Circulation. 2003 Oct 28;108(17 ):2107-12</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14530200</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Med. 2006 Feb;12(2):178-80</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16462800</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Arterioscler Thromb Vasc Biol. 2005 Dec;25(12):2642-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16239591</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Circulation. 2000 Dec 12;102(24):2919-22</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11113040</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 1994 Aug 26;265(5176):1237-40</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7520605</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Immunol. 2011 Mar;12(3):204-12</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21321594</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Lipid Res. 2007 Feb;48(2):425-33</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17093289</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Arterioscler Thromb Vasc Biol. 2015 Aug;35(8):1770-3</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26088575</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Lipid Res. 2005 Jul;46(7):1353-63</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15897601</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):821-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7846059</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Immunol. 2010 Feb;40(2):443-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19941312</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Arterioscler Thromb Vasc Biol. 2011 Jul;31(7):1506-16</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21677293</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Immunol Rev. 1994 Dec;142:301-20</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7698798</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Sci (Lond). 2001 Nov;101(5):523-31</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11672458</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Interferon Cytokine Res. 2002 Jun;22(6):661-70</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12162876</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Arterioscler Thromb Vasc Biol. 2003 Mar 1;23(3):454-60</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12615659</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Intern Med. 2011 May;269(5):546-56</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21114693</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Circulation. 2001 Jul 10;104(2):197-202</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11447086</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur Heart J. 2008 Sep;29(18):2218-26</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18664466</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Circ Res. 2012 Jan 6;110(1):e1-12</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22034493</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell. 2008 May 30;133(5):775-87</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18510923</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Circulation. 2009 Aug 4;120(5):417-26</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19620499</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Immunol Rev. 2008 Jun;223:284-99</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18613843</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Arterioscler Thromb Vasc Biol. 2012 Mar;32(3):605-12</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22223728</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Arterioscler Thromb Vasc Biol. 2001 Jan;21(1):95-100</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11145939</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Circ Res. 2016 Nov 11;119(11):1190-1203</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">27635087</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Annu Rev Immunol. 2012;30:531-64</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22224781</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Med. 2003 Jan-Feb;9(1-2):10-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12765335</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Am Coll Cardiol. 2007 Dec 11;50(24):2313-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18068040</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Invest. 2002 Mar;109(6):745-53</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11901183</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Circulation. 2004 Oct 5;110(14):2047-52</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15451805</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Lipid Res. 2011 Oct;52(10):1829-36</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21821825</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int Immunol. 2013 Nov;25(11):615-22</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24154816</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Circulation. 2011 Mar 15;123(10):1083-91</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21357823</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nature. 1997 Oct 16;389(6652):737-42</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9338786</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Immunol. 2009 Nov;10(11):1178-84</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19783988</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Invest. 2013 Jan;123(1):27-36</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23281407</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Physiol Regul Integr Comp Physiol. 2008 Oct;295(4):R1109-14</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18650318</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Arterioscler Thromb Vasc Biol. 2015 Jan;35(1):40-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25301842</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Exp Med. 2010 May 10;207(5):1081-93</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20439543</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Blood. 2006 Jun 1;107(11):4240-3</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16467202</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E15 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000E15 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:28087520
   |texte=   Atheroprotective vaccination with MHC-II-restricted ApoB peptides induces peritoneal IL-10-producing CD4 T cells.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:28087520" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a MersV1 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021